XML 43 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
 3 Months Ended 12 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Dec. 31, 2014
Dec. 31, 2013
Operating activities        
Net loss $ (2,447,320)us-gaap_NetIncomeLoss $ (972,898)us-gaap_NetIncomeLoss $ (7,917,853)us-gaap_NetIncomeLoss $ (4,044,971)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 4,323us-gaap_Depreciation 1,790us-gaap_Depreciation 12,241us-gaap_Depreciation 35,366us-gaap_Depreciation
Stock-based compensation 82,772us-gaap_ShareBasedCompensation 81,442us-gaap_ShareBasedCompensation 604,976us-gaap_ShareBasedCompensation 326,644us-gaap_ShareBasedCompensation
Change in fair value of warrants (19,807)mbvx_ChangeInFairValueOfWarrant    (475,422)mbvx_ChangeInFairValueOfWarrant  
Increase (decrease) in operating assets and liabilities:        
Grants receivable (155,195)us-gaap_IncreaseDecreaseInReceivables    (84,344)us-gaap_IncreaseDecreaseInReceivables 19,845us-gaap_IncreaseDecreaseInReceivables
Other receivables 2,275us-gaap_IncreaseDecreaseInOtherReceivables    28,316us-gaap_IncreaseDecreaseInOtherReceivables  
Prepaid expenses - clinical operations       539,633us-gaap_IncreaseDecreaseInPrepaidExpense
Prepaid expenses and other 44,474us-gaap_IncreaseDecreaseInPrepaidExpensesOther (11,559)us-gaap_IncreaseDecreaseInPrepaidExpensesOther (117,004)us-gaap_IncreaseDecreaseInPrepaidExpensesOther 13,061us-gaap_IncreaseDecreaseInPrepaidExpensesOther
Accounts payable 753,184us-gaap_IncreaseDecreaseInAccountsPayable 212,040us-gaap_IncreaseDecreaseInAccountsPayable 1,246,270us-gaap_IncreaseDecreaseInAccountsPayable 21,946us-gaap_IncreaseDecreaseInAccountsPayable
Accrued clinical operations and site costs 22,847us-gaap_IncreaseDecreaseInAccruedLiabilities (302,773)us-gaap_IncreaseDecreaseInAccruedLiabilities (279,413)us-gaap_IncreaseDecreaseInAccruedLiabilities 128,485us-gaap_IncreaseDecreaseInAccruedLiabilities
Accrued compensation 88,434us-gaap_IncreaseDecreaseInAccruedSalaries (80,123)us-gaap_IncreaseDecreaseInAccruedSalaries (789,014)us-gaap_IncreaseDecreaseInAccruedSalaries 80,138us-gaap_IncreaseDecreaseInAccruedSalaries
Related party liabilities       45,000us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties
Other accrued expenses 200,483us-gaap_IncreaseDecreaseInOtherAccruedLiabilities    109,228us-gaap_IncreaseDecreaseInOtherAccruedLiabilities (16,365)us-gaap_IncreaseDecreaseInOtherAccruedLiabilities
Net cash used in operating activities (1,423,530)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (1,072,081)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (7,662,019)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (2,851,218)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Investing activities        
Purchases of property and equipment (28,867)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (1,153)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (44,807)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (8,718)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Proceeds from acquisition of Telik, Inc.     1,497,283us-gaap_CashAcquiredFromAcquisition  
Net cash used in investing activities (28,867)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (1,153)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations 1,452,476us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (8,718)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Financing activities        
Issuances of preferred stock, net of issuance costs    2,973,655us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock 2,973,655us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock 2,792,993us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
Issuances of common stock, net of issuance costs 4,714,726us-gaap_ProceedsFromIssuanceOfCommonStock    2,884,333us-gaap_ProceedsFromIssuanceOfCommonStock  
Net cash provided by financing activities 4,714,726us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 2,973,655us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 7,332,432us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 2,792,993us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Net change in cash and cash equivalents 3,262,329us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 1,900,421us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 1,122,889us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (66,943)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at beginning of year 1,477,143us-gaap_CashAndCashEquivalentsAtCarryingValue 354,254us-gaap_CashAndCashEquivalentsAtCarryingValue 354,254us-gaap_CashAndCashEquivalentsAtCarryingValue 421,197,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at end of year 4,739,472us-gaap_CashAndCashEquivalentsAtCarryingValue 2,254,675us-gaap_CashAndCashEquivalentsAtCarryingValue 1,477,143us-gaap_CashAndCashEquivalentsAtCarryingValue 354,254us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosures of cash flow information:        
Cash paid during the period for income taxes     800us-gaap_IncomeTaxesPaidNet 1,526us-gaap_IncomeTaxesPaidNet
Supplemental disclosures of non-cash investing and financing information:        
Deemed dividend on beneficial conversion feature for preferred stock 17,852,921mbvx_DeemedDividendOnBeneficialConversionFeatureForPreferredStock 2,214,910mbvx_DeemedDividendOnBeneficialConversionFeatureForPreferredStock 2,214,911mbvx_DeemedDividendOnBeneficialConversionFeatureForPreferredStock 691,812mbvx_DeemedDividendOnBeneficialConversionFeatureForPreferredStock
Accretion of redemption value for Series A-1 and B preferred stock 93,234mbvx_AccretionOfRedemptionValueForSeriesAOneAndBPreferredStock 31,934mbvx_AccretionOfRedemptionValueForSeriesAOneAndBPreferredStock 444,992mbvx_AccretionOfRedemptionValueForSeriesAOneAndBPreferredStock  
Issuance of common stock for accounts payable    240,000us-gaap_StockIssued1 240,000us-gaap_StockIssued1  
Goodwill on acquisition of Telik, Inc.     6,826,003us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1  
Conversion of Series A-1 redeemable preferred stock into common stock 162,968us-gaap_ConversionOfStockAmountConverted1       
Conversion of Series C preferred stock to common stock 966mbvx_ConversionOfSeriesCPreferredStockToCommonStock       
Conversion of Series B preferred stock to common stock 160,380mbvx_ConversionOfSeriesBPreferredStockToCommonStock       
Exchange of Series A-1 preferred stock and warrants into common stock and Series D preferred stock 13,111,280mbvx_ExchangeOfSeriesA1PreferredStockAndWarrantsIntoCommonStockAndSeriesDPreferredStock       
Exchange of Series B preferred stock and warrants into common stock and Series D preferred stock 10,451,784mbvx_ExchangeOfSeriesBPreferredStockAndWarrantsIntoCommonStockAndSeriesDPreferredStock       
Acquisition of MabVax Therapeutics Holdings in relation to the merger     4,705,726us-gaap_NoncashMergerRelatedCosts  
Warrants exercised to purchase common stock on a cashless basis to purchase 488,659 shares of common stock. See Note 7.     $ 4,887mbvx_WarrantsToPurchaseCommonStockValue